52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study Hahn, S., Pena, L., Day, J. W., Gambello, M., Gibson, J. B., Hillman, R., Kronn, D., Stockton, D., Leslie, N., Tanpaiboon, P., Wang, R., Haack, K., Sparks, S., Zhao, Y., Kishnani, P. S., Pompe ADVANCE Study Consortium ACADEMIC PRESS INC ELSEVIER SCIENCE. 2016: S54

View details for DOI 10.1016/j.ymgme.2015.12.281

View details for Web of Science ID 000370888100124